You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Affordable sialoglycans and associated reagents for expanded chemoenzymatic production
SBC: Integrated Micro-Chromatography Systems, Inc. Topic: 300Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
CN-105 Improves Functional Outcome After Intracranial Hemorrhage
SBC: AegisCN LLC Topic: 106Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Programming Metabolically Fit TILs for Immunotherapy
SBC: LIPO-IMMUNO TECH LLC Topic: NCIABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Improved Treatment of Colorectal Cancer with CF10
SBC: Deep Creek Pharma, LLC Topic: 102PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of peptide nucleic acid antibiotics
SBC: NUBAD LLC Topic: NIAIDThe world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of the UValidate platform for the profiling of topically applied chemical agents.
SBC: AMELIA TECHNOLOGIES LLC Topic: RProject Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
MegaTrans – human transporter machine learning models
SBC: COLLABORATIONS PHARMACEUTICALS INC Topic: 400Summary Being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effects. Conversely, some drug transporters can be used for targeting molecules to specific organs and this may have considerable utility. Understanding the interactions of novel drugs, natural products and environme ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Good Bowls: Empowering Communities to Achieve Good Food Access and Health Equity
SBC: Equiti Foods, LLC Topic: 100Abstract - Low-income and ethnic minority status as well as rural residence are strong predictors of poor health. Contributors to high chronic disease rates include food insecurity (lack of access to affordable, nutritious food) and lack of economic opportunity. Rural poverty in the Southeast is exacerbated by historical discrimination against Black farmers, and ongoing structural racism. At the i ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
SBC: Mabloc, LLC Topic: NIAIDAbstract PROJECT SUMMARY/ABSTRACT The recent groundbreaking experiment using a single neutralizing monoclonal antibody (nmAb) to reduce the death rate in Ebola virus (EBOV)-infected individuals highlights the importance of this class of drug in the treatment of infectious disease. In August 2019, Dr. Anthony Fauci announced that administration of mAb114 had reduced the death rate from 70% to appro ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health